Skip to main content
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;27(5):281–286. doi: 10.1002/clc.4960270509

Plasma vascular endothelial growth factor level is elevated in patients with multivessel coronary artery disease

Kei Nakajima 1,, Shinji Tabata 1, Takeshi Yamashita 2, Masatoshi Kusuhara 1, Koh Arakawa 1, Reiko Ohmori 1, Atsushi Yonemura 1, Kenji Higashi 1, Makoto Ayaori 1, Haruo Nakamura 2, Fumio Ohsuzu 1
PMCID: PMC6654355  PMID: 15188944

Abstract

Background: Vascular endothelial growth factor (VEGF) has been implicated in both angiogenesis and ischemia. However, the relationship between plasma VEGF level and coronary artery disease remains unknown.

Hypothesis: Plasma VEGF level may be associated with severe coronary artery disease and other cardiovascular risk factors.

Methods: We examined plasma VEGF concentration and coronary risk factors in 73 patients who underwent coronary angiography and 70 apparently healthy control subjects. According to the number of the three major coronary vessels with significant (≥ 75%) stenosis, we divided the patients into two groups: the mild stenosis group (0‐ and single‐vessel disease, n = 36) and the severe stenosis group (double‐ and triple‐vessel disease, n = 37).

Results: The log VEGF value of the severe stenosis group was significantly higher than that of the mild stenosis (p < 0.05) and control groups (p < 0.05). Furthermore, there was a significant positive trend in the log VEGF value according to the number of vessels with significant stenosis (p = 0.016). However, there was no significant difference in log VEGF value between the mild stenosis and control groups. Soluble vascular cellular adhesion molecule, soluble intracellular adhesion molecule, and other coronary risk factors were found to be associated with the presence of vessel stenosis.

Conclusion: Unlike established coronary risk factors, the plasma VEGF level may be associated with only severe coronary ischemia such as multiple coronary vessel disease.

Keywords: vascular endothelial growth factor, ischemia, atherosclerosis, severity, coronary artery disease, cytokine

Full Text

The Full Text of this article is available as a PDF (46.5 KB).

References

  • 1. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306–1309 [DOI] [PubMed] [Google Scholar]
  • 2. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470–1478 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Ferrara N, Davis‐Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4–25 [DOI] [PubMed] [Google Scholar]
  • 4. Klagsbrun M, D'Amore PA: Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996; 7: 259–270 [DOI] [PubMed] [Google Scholar]
  • 5. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia‐initiated angiogenesis. Nature 1992; 359: 843–845 [DOI] [PubMed] [Google Scholar]
  • 6. Brogi E, Wu T, Namiki A, Isner JM: Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994; 90: 649–652 [DOI] [PubMed] [Google Scholar]
  • 7. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E: Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: Implications for coronary angiogenesis. Cardiovasc Res 1994; 28: 1176–1179 [DOI] [PubMed] [Google Scholar]
  • 8. Fuhrmann‐Benzakein E, Ma MN, Rubbia‐Brandt L, Mentha G, Ruefenacht D, Sappino AP, Pepper MS: Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int J Cancer 2000; 85: 40–45 [DOI] [PubMed] [Google Scholar]
  • 9. Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR: Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999; 54: 523–527 [DOI] [PubMed] [Google Scholar]
  • 10. Agrawal R, Conway GS, Sladkevicius P, Payne NN, Bekir J, Campbell S, Tan SL, Jacobs HS: Serum vascular endothelial growth factor (VEGF) in the normal menstrual cycle: Association with changes in ovarian and uterine Doppler blood flow. Clin Endocrinol (Oxf) 1999; 50: 101–106 [DOI] [PubMed] [Google Scholar]
  • 11. Sharkey AM, Cooper JC, Balmforth JR, McLaren J, Clark DE, Charnock‐Jones DS, Morris NH, Smith SK: Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by pre‐eclampsia. Eur J Clin Invest 1996; 26: 1182–1185 [DOI] [PubMed] [Google Scholar]
  • 12. Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E, Kawaguchi T, Ariyoshi M, Saiki T, Sakamoto M, Nagata K, Sata M, Matsuo K, Tanikawa K: Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998; 27: 377–380 [DOI] [PubMed] [Google Scholar]
  • 13. Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de Water L, Senger DR: Vascular permeability factor/vascular endothelial growth factor: An important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995; 107: 233–235 [DOI] [PubMed] [Google Scholar]
  • 14. Gensini GG: Amore meaningful scoring system for determining the severity of coronary heart disease (letter). Am J Cardiol 1983; 51: 606 [DOI] [PubMed] [Google Scholar]
  • 15. Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, Kyria‐kopoulos A: The expression of the adhesion molecules ICAM‐1, VCAM‐1, PECAM, and E‐selectin in human atherosclerosis. J Pathol 1993; 171: 223–229 [DOI] [PubMed] [Google Scholar]
  • 16. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E: Circulating adhesion molecules VCAM‐1, ICAM‐1, and E‐selectin in carotid atherosclerosis and incident coronary heart disease cases: The atherosclerosis risk in communities (ARIC) study. Circulation 1997; 96: 4219–4225 [DOI] [PubMed] [Google Scholar]
  • 17. Peter K, Nawroth P, Conradt C, Nordt T, Weiss T, Boehme M, Wunsch A, Allenberg J, Kubler W, Bode C: Circulating vascular cell adhesion molecule‐1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule‐1, E‐selectin, P‐selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 1997; 17: 505–512 [DOI] [PubMed] [Google Scholar]
  • 18. Superko HR, Krauss RM: Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994; 90: 1056–1069 [DOI] [PubMed] [Google Scholar]
  • 19. Steinberg D, Gotto AM Jr: Preventing coronary artery disease by lowering cholesterol levels: Fifty years from bench to bedside. J Am Med Assoc 1999; 282: 2043–2050 [DOI] [PubMed] [Google Scholar]
  • 20. Arakawa K, Isoda K, Sugiyabu Y, Fukuda M, Nishizawa K, Shibuya T, Nakamura H: Intimal proliferation after stenting reflected by increased stent‐to‐vessel cross‐sectional area ratio: Serial intravascular ultrasound study. J Cardiol 1998; 32: 379–389 [PubMed] [Google Scholar]
  • 21. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992. Dec; 267: 26031–26037 [PubMed] [Google Scholar]
  • 22. Kondo S, Matsumoto T, Yokoyama Y, Ohmori I, Suzuki H: The shortest isoform of human vascular endothelial growth factor/vascular permeability factor (VEGF/VPF121) produced by Saccharomyces cerevisiae promotes both angiogenesis and vascular permeability. Biochim Biophys Acta 1995. Feb; 1243: 195–202 [DOI] [PubMed] [Google Scholar]
  • 23. Lochen ML: The Tromso study: The prevalence of exercise‐induced silent myocardial ischaemia and relation to risk factors for coronary heart disease in an apparently healthy population. Eur Heart J 1992; 13: 728–731 [DOI] [PubMed] [Google Scholar]
  • 24. Osterspey A, Treis‐Muller I, Gunther H, Eggeling T, Siglow C, Gedicke V, Hopp H, Diewitz M, Osterhues H, Hilger HH: Silent ischaemia in asymptomatic “healthy” individuals with coronary risk factors. Eur Heart J 1988;(suppl N): 65–69 [DOI] [PubMed]
  • 25. Reardon MF, Nestel PJ, Craig IH, Harper RW: Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation 1985; 71: 881–888 [DOI] [PubMed] [Google Scholar]
  • 26. Sullivan DR, Marwick TH, Freedman SB: A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J 1990; 119: 1262–1267 [DOI] [PubMed] [Google Scholar]
  • 27. Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K: Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: Possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998; 98: 2108–211 [DOI] [PubMed] [Google Scholar]
  • 28. Moussa I, Moses JW: Angiogenesis for treatment of ischemic heart disease: Should we worry about progression of atherosclerosis (letter)? Circulation 1999; 100: e109 [DOI] [PubMed] [Google Scholar]
  • 29. O'Brien ER, Garvin MR, Dev R, Stewart DK, Hinohara T, Simpson JB, Schwartz SM: Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994; 145: 883–894 [PMC free article] [PubMed] [Google Scholar]
  • 30. Ogawa H, Suefuji H, Soejima H, Nishiyama K, Misumi K, Takazoe K, Miyamoto S, Kajiwara I, Sumida H, Sakamoto T, Yoshimura M, Kugiyama K, Yasue H, Matsuo K: Increased blood vascular endothelial growth factor levels in patients with acute myocardial infarction. Cardiology 2000; 93: 93–99 [DOI] [PubMed] [Google Scholar]
  • 31. Hojo Y, Ikeda U, Zhu Y, Okada M, Ueno S, Arakawa H, Fujikawa H, Katsuki T, Shimada K: Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol 2000; 35: 968–973 [DOI] [PubMed] [Google Scholar]
  • 32. Servos S, Zachary I, Martin JF: VEGF modulates NO production: The basis of a cytoprotective effect? Cardiovasc Res 1999; 41: 509–510 [DOI] [PubMed] [Google Scholar]
  • 33. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK: During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996; 2: 992–997 [DOI] [PubMed] [Google Scholar]
  • 34. Swerlick RA, Swerlick RA: Angiogenesis. J Dermatol 1995; 22: 845–852 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES